Systemic Fibrinolytic Activity and Inhibitor Levels During Treatment of Deep Vein Thrombosis with Urokinase and Streptokinase

Summary

In a prospective, randomized trial 33 patients with deep vein thrombosis were treated either with 2,200 or 1,100 IU/kg/h urokinase or with 100,000 IU/h streptokinase for at least 6 days. While streptokinase was given continuously, urokinase was administered intermittently (12 hr urokinase alternating with 12 hr heparin).

Urokinase treatment resulted in a dose-dependent fibrinolytic state with shortening of the euglobulin clot lysis time, easily demonstrable amidolytic activity and moderate decrease of plasminogen. At the end of each urokinase-free interval the fibrinolytic activity had mostly faded, but was reproducibly elicited again by each new urokinase administration. Streptokinase immediately evoked the customary, intense fibrinolytic state, which progressively tapered off as plasminogen fell to 1% of its pretreatment concentration. In all treatment groups α-2-antiplasmin dropped to approximately 40% of its initial value during the first 12 hr with a further decrease to about 20% after 6 days, α-2-macroglo- bulin fell only moderately with either urokinase regimen, whereas it decreased progressively to 45% under streptokinase.

While the fibrinolytic activity decreased under streptokinase over the 6-day infusion period, it appeared to increase with each successive urokinase infusion particularly with 1100 IU/kg/h. Thus the final euglobulin clot lysis times and the final fibrinogen concentrations were similar in all three treatment groups on the sixth day.

Keywords

Streptokinase dosage - Urokinase dosage - Fibrinolytic activity - Plasma inhibitors of fibrinolysis

• References

• 1 Potron G, Seys A, Bajolet A, Elaerts R, Guerin R, Leroux B, Morice JC, Pire J-C. Intérêt du traitement thrombolytique par l’urokinase à doses moyennes (Etude de 20 observations). Presented at Journées Régionales Franco-Italiennes d’Anesthésie - Réanimation. (Provence-Ligurie). Toulon: 1973. pp 1-12
• 2 Tilsner V, Greul W. Thrombolytische Therapie mit Urokinase. MMW 1975; 117: 865-868
• 3 Niessner H, Czembirek H, Lechner K, Nowotny C, Thaler E. Grundlagen der Dosierung von Urokinase und Therapieüberwachung. In: Urokinase Workshop 1977 in Gravenbruch. Tilsner V. (Ed) Papillon; Freiburg: 1978. pp 16-31
• 4 Trübestein G, Brecht T, Glänzer K, Koischwitz D, Etzel F. Die fibrinolytische Therapie mit Urokinase bei älterer Phlebothrombose. Med Klin 1979; 74: 1404-1411
• 5 Theiss W, Schlund J, Kriessmann A, Lutilsky L, Sauer E, Wirtzfeld A. Die Behandlung tiefer Venenthrombosen mit Urokinase. Klin Wochenschr 1980; 58: 521-526
• 6 Zimmermann R, Harenberg J, Mörl H, Kuhn HM, Wahl P, Gerhardt P. Thrombolytische Therapie der tiefen Beinvenenthrombose mit Urokinase. Klin Wochenschr 1982; 60: 489-496
• 7 van de Loo JC W, Kriessmann A, Trübestein G, Knoch K, De Swart CA M, Asbeck F, Marbet GA, Schmitt HE, Sewell AF, Duckert F, Theiss W, Ritz R. Controlled multicenter pilot study of urokinaseheparin and streptokinase in deep vein thrombosis. Thromb Haemostas 1983; 50: 660-663
• 8 MacFarlane RG, Pilling J. Observations on fibrinolysis. Plasminogen, plasmin, and antiplasmin content of human blood Lancet 1946; 2: 562-565
• 9 Claeson G, Friberger P, Knös M, Eriksson E. Methods for determination of prekallikrein in plasma, glandular kallikrein and urokinase. Haemostasis 1978; 7: 76-78
• 10 Friberger P, Knös M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, anitplasmin and plasminogen by means of substrate S-2251. Haemostas 1978; 7: 138-145
• 11 Lämmle B, Eichlisberger R, Marbet GA, Duckert F. Amidolytic activity in normal human plasma assessed with chromogenic substrates. Thromb Res 1979; 16: 245-254
• 12 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 13 Schmitz-Hübner U, Nachbar J, Asbeck F. The determination of antithrombin III, α-2-macroglobulin and α-2-antiplasmin in plasma by Laser nephelometry. J Clin Chem Clin Biochem 1980; 18: 221-225
• 14 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235-254
• 15 Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951; 37: 316-320
• 16 Merskey C, Kleiner GJ, Johnson AJ. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 1966; 28: 1-18
• 17 Urokinase Pulmonary Embolism Trial Study Group. Urokinasepulmonary embolism trial. Phase 1 Results JAMA 1970; 214: 2163-2172
• 18 Urokinase Pulmonary Embolism Trial Study Group. Urokinasestreptokinase embolism trial. Phase 2 results JAMA 1974; 229: 1606-1613
• 19 Theiss W, Kriessmann A, Wirtzfeld A. Laborbefunde und klinische Ergebnisse bei thrombolytischer Langzeittherapie mit Urokinase. Herz/Kreisl 1975; 7: 631-637
• 20 Sasahara AA, Cannilla JE, Belko JS, Morse RL, Criss AJ. Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent N Engl J Med 1967; 277: 1168-1173
• 21 Genton E, Wolf PS. Urokinase therapy in pulmonary thromboembolism. Am Heart J 1968; 76: 628-637
• 22 Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959; 38: 1086-1095
• 23 Johnson AJ, McCarty WR. Some aspects of the mechnism of thrombolysis. Thrombos Diathes Haemmorrh 1961; 5: 391-395
• 24 Samama M, Conard J. Biological results during urokinase therapy at different doses. In: Thrombosis and urokinase. Paoletti R, Sherry S. (Eds) Academic Press; London: 1977. pp 243-244
• 25 Juhan I, Calas MF, Buonocore M, Mathieu P, Isnard G, Cazenave B, Serradimigni A. Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin. Thromb Haemostas 1979; 42: 945-954
• 26 Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. The development of urokinase as a thromoblytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous infusion J Lab Clin Med 1965; 65: 713-731
• 27 Urokinase Pulmonary Embolism Trial Study Group. The urokinase pulmonary embolism trial. A National cooperative study Circulation 1973; 47 Suppl (Suppl. 02) 1-108
• 28 Ducken F, Burkart F, Hecker S, Bounameaux Y, Batschelt E. Controlled trial of urokinase in myocardial infarction. A European collaborative study Lancet 1975; 2: 624-626
• 29 Marder VJ, Donahoe JF, Bell WR, Cranley JJ, Kwaan HC, Sasahara AA, Barlow GH. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. J Lab Clin Med 1978; 92: 721-729
• 30 Collen D, Verstraete M. α-2-antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy. Thromb Res 1979; 14: 631-639
• 31 Ueno T, Kobayashi N, Maekawa T. Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. Thromb Haemostas 1979; 42: 885-894
• 32 Trübestein G. Indikationen und Ergebnisse mit Urokinase bei Gefäß- verschlüssen. Dtsch Med Wochenschr 1976; 101: 1919-1920
• 33 Duckert F, Müller G, Nymann D, Benz A, Prisender S, Madar G, da Silva MA, Widmer LK, Schmitt HE. Treatment of deep vein thrombosis with streptokinase. Br Med J 1975; 1: 479-481
• 34 Tilsner V. Therapie mit Urokinase bei thrombotischen Verschlüssen der Venen. In: Urokinase Workshop 1977 in Gravenburch. Tilsner V. (Ed) Papillon; Freiburg: 1978. pp 103-119
• 35 Theiss W, Wirtzfeld A, Fink U, Maubach P. The success rate of fibrinolytic therapy in fresh and old thrombosis of the iliac and femoral veins. Angiology 1983; 34: 61-69